Financial results for the period ended Jun 30, 2026
As filed · Alivus Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
EarningsMajormateriality 77 out of 100
What happened
FactALIVUS has approved its unaudited financial results for the first quarter ended June 30, 2026, during a Board meeting held on July 30, 2026. The results and the Limited Review Report of the Auditor are enclosed and will also be available on the company's website.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Going forward, we continue to expect high single-digit revenue growth for FY’26, driven by strong and profitab (management committed by FY26)
- In about 1 to 1.5 years, we can get the project going. (management committed by H1 FY27)
Evidence
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%